Skip to main content
Signal8
Launch Terminal

Moleculin Biotech, Inc. (MBRX)

Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company dedicated to advancing therapeutic candidates designed to combat highly aggressive cancers and viral infections. Their primary investigational drug, Annamycin, is currently undergoing Phase 1/2 clinical trials. These trials aim to assess its efficacy against acute myeloid leukemia (AML) that has relapsed or is resistant to prior therapies, as well as malignancies that have spread to the lungs. WP1066, a prominent immune/transcription modulator for the company, is presently in Phase I studies, targeting both adult and pediatric brain tumors, pancreatic cancer, and other types of aggressive malignancies. Further, the firm is developing WP1220, an analog of WP1066, intended for topical application in treating cutaneous T-cell lymphoma. Another compound, WP1122, is under development for glioblastoma multiforme and COVID-19. Moleculin Biotech has established collaboration agreements and partnerships with organizations such as MD Anderson, Animal Life Sciences, LLC, and WPD Pharmaceuticals Sp z.o.o. The company was founded in 2015 and maintains its principal offices in Houston, Texas.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Moleculin Biotech, Inc. logo

Moleculin Biotech, Inc.

NASDAQ:MBRXHealthcare
-9.40%$7.90
AH$7.90+0.00%vs close
Mkt Cap-
Float1.02M
O/S-
Vol
$ Vol
RVOL
Inst Own0.9%
Earnings
Dilution
Moleculin Biotech, Inc. logoNASDAQ:MBRX$7.90-9.40%
Phase Distribution
8 lead-sponsored trials·1 active·7 completed
Phase 12
Phase 1/24
Phase 21
Phase 2/31
(1 more as collaborator)
Status Overview
Recruiting1
Completed7

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 2/3
    Recruiting

    L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML

    Placebo in combination with Cytarabine Injection, Liposomal Annamycin Injection in combination with Cytarabine Injection

    Acute Myeloid Leukaemia (AML)

    Enrollment
    312
    Start
    Mar 2025
    Primary Completion
    Aug 2029est.
    Completion
    Aug 2030est.
    NCT06788756
  • Phase 2
    Completed

    Paired Psoriasis Lesion, Comparative, Study to Evaluate MOL4239 in Psoriasis

    MOL4239, Placebo

    Psoriasis

    Enrollment
    21
    Start
    Mar 2013
    Primary Completion
    Aug 2013
    Completion
    Aug 2013
    NCT01826201
  • Phase 1/2
    Completed

    Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML)

    Liposomal Annamycin

    Leukemia, Myeloid, Acute

    Enrollment
    7
    Start
    Mar 2018
    Primary Completion
    Jan 2020
    Completion
    Jun 2020
    NCT03315039
  • Phase 1/2
    Completed

    Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML)

    Liposomal Annamycin

    Leukemia, Myeloid, Acute

    Enrollment
    20
    Start
    Dec 2018
    Primary Completion
    Feb 2022
    Completion
    Feb 2022
    NCT03388749
  • Phase 1/2
    Completed

    Study of Liposomal Annamycin for the Treatment of Subjects with Soft-Tissue Sarcomas (STS) with Pulmonary Metastases

    Liposomal Annamycin (L-Annamycin)

    Sarcoma,Soft Tissue, Pulmonary Metastasis

    Enrollment
    36
    Start
    Jun 2021
    Primary Completion
    Sep 2022
    Completion
    Aug 2024
    NCT04887298
  • Phase 1/2
    Completed

    Study of Liposomal Annamycin in Combination With Cytarabine for the Treatment of Subjects With Acute Myeloid Leukemia (AML)

    Liposomal Annamycin, Cytarabine

    Leukemia, Myeloid, Acute

    Enrollment
    22
    Start
    Sep 2022
    Primary Completion
    Aug 2023
    Completion
    Aug 2023
    NCT05319587
  • Phase 1
    Completed

    Study of WP1220 for the Treatment of Adult Subjects With Cutaneous T-Cell Lymphoma (CTCL)

    WP1220

    Cutaneous T-Cell Lymphoma/Mycosis Fungoides

    Enrollment
    5
    Start
    Mar 2019
    Primary Completion
    Nov 2019
    Completion
    Nov 2020
    NCT04702503
  • Phase 1
    Completed

    Study to Assess the Safety and Pharmacokinetics of WP1122 in Healthy Volunteers

    WP1122, Placebo

    Healthy Volunteer

    Enrollment
    48
    Start
    May 2022
    Primary Completion
    Oct 2022
    Completion
    Oct 2022
    NCT05195723
Search ClinicalTrials.gov for “Moleculin Biotech”